Pfizer announced it too has signed a partnership with Seattle Genetics to make antibody-drug conjugates (ADCs) versus another cancer target. Pfizer agree to pay $8 M iupfront with milestones that could total up to another $200 M.
Seattle Genetics confirmed that it now has 10 such partnerships in place. The most visible is its partnership on SGN-35 with Takeda (Millenium) as a treatment for Hodgkin's disease and anaplastic large cell lymphoma. They indicate that more than $145 M has been generated from licensing payments. Other partners include Genetech, Bayer and GSK.
Genentech's most prominent deal in the ADC arena is with Immunogen for its much watched therapeutic agent T-DM1 for the treatment of breast cancer. Genetech's latest deal is with Spirogen for its version of ADC technology. Spirogen focuses on a class of low-molecular weight, sequence-specific, DNA-interactive drugs designed to treat gene-mediated cancers. Its technology is based on the modification of members of a group of natural antibiotics called pyrrolobenzodiazepines (PBDs).
Per the agreement, Spirogen will take the responsibility to manufacture and synthesize drug reagents to generate ADCs and investigate their potential therapeutic utility. Genentech will have the exclusive license for the development and commercialization of licensed products. Spirogen CEO Christopher Martin said that they are hopeful that the collaboration with Genentech will allow Spirogen to accelerate the development of ADCs based on the PBD drugs.
The financial terms fo the deal were not disclosed.
Posted by Bruce Lehr Jan 6th 2011.